Version 1
: Received: 28 June 2024 / Approved: 1 July 2024 / Online: 1 July 2024 (07:37:34 CEST)
How to cite:
Nowak-Jary, J.; Płóciennik, A.; Machnicka, B. Functionalized Magnetic Fe3O4 Nanoparticles for Targeted Methotrexate Delivery in Ovarian Cancer Therapy. Preprints2024, 2024070042. https://doi.org/10.20944/preprints202407.0042.v1
Nowak-Jary, J.; Płóciennik, A.; Machnicka, B. Functionalized Magnetic Fe3O4 Nanoparticles for Targeted Methotrexate Delivery in Ovarian Cancer Therapy. Preprints 2024, 2024070042. https://doi.org/10.20944/preprints202407.0042.v1
Nowak-Jary, J.; Płóciennik, A.; Machnicka, B. Functionalized Magnetic Fe3O4 Nanoparticles for Targeted Methotrexate Delivery in Ovarian Cancer Therapy. Preprints2024, 2024070042. https://doi.org/10.20944/preprints202407.0042.v1
APA Style
Nowak-Jary, J., Płóciennik, A., & Machnicka, B. (2024). Functionalized Magnetic Fe<sub>3</sub>O<sub>4</sub> Nanoparticles for Targeted Methotrexate Delivery in Ovarian Cancer Therapy. Preprints. https://doi.org/10.20944/preprints202407.0042.v1
Chicago/Turabian Style
Nowak-Jary, J., Artur Płóciennik and Beata Machnicka. 2024 "Functionalized Magnetic Fe<sub>3</sub>O<sub>4</sub> Nanoparticles for Targeted Methotrexate Delivery in Ovarian Cancer Therapy" Preprints. https://doi.org/10.20944/preprints202407.0042.v1
Abstract
Magnetic Fe3O4 nanoparticles (MNPs) functionalized with (3-aminopropylo)trietoksysilan (APTES) or N-carboxymethylchitosan (CMC) were proposed as nanocarriers of methotrexate (MTX) against ovarian cancer cell lines. The successful functionalization of the obtained nanostructures was confirmed by FT-IR spectroscopy. Nanoparticles were characterized by transmission electron spectroscopy (TEM) and dynamic light scattering (DLS) techniques. Their potential zeta, magnetization, and hyperthermic properties were also explored. MTX was conjugated with nanocarriers by ionic bonds or by amide bonds. For all three types of nanostructures, the drug release kinetics were examined at different pH and temperatures. The MTT assay showed no toxicity of MNPs[APTES] and MNPs[CMC]. Finally, the cytotoxicity of the nanostructures with MTX attached was measured towards the ovarian cancer cells model sensitivity and resistance to methotrexate in simplistic 2D and spheroid 3D conditions. The results of cytotoxicity tests of the tested nanostructures showed similar values for inhibiting the proliferation of ovarian cancer cells as methotrexate in its free form. Conjugating MTX with nanoparticles allows the drug to be directed to the target site using an external magnetic field, reducing overall toxicity. Combining this approach with hyperthermia could enhance the therapeutic effect in vivo compared to free MTX, though further research on advanced 3D models is needed.
Keywords
magnetic iron oxide nanoparticles; methotrexate; ovarian cancer; cytotoxicity
Subject
Chemistry and Materials Science, Nanotechnology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
